| DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study M Di Iorio, CE Cook, KMM Vanni, NJ Patel, KM D'Silva, X Fu, J Wang, ... Seminars in arthritis and rheumatism 55, 152025, 2022 | 42 | 2022 |
| Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study G Qian, X Wang, NJ Patel, Y Kawano, X Fu, CE Cook, KMM Vanni, ... The Lancet Rheumatology 5 (3), e139-e150, 2023 | 35 | 2023 |
| Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study G Figueroa-Parra, EL Gilbert, MO Valenzuela-Almada, S Vallejo, ... The Lancet Rheumatology 4 (11), e765-e774, 2022 | 32 | 2022 |
| Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: a cohort study NJ Patel, X Wang, X Fu, Y Kawano, C Cook, KMM Vanni, G Qian, ... Seminars in arthritis and rheumatism 58, 152108, 2023 | 29 | 2023 |
| Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave Y Kawano, NJ Patel, X Wang, CE Cook, KMM Vanni, EN Kowalski, ... Annals of the rheumatic diseases 81 (12), 1742-1749, 2022 | 29 | 2022 |
| Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases NJ Patel, C Cook, K Vanni, X Fu, X Wang, Y Kawano, G Qian, B Hang, ... Annals of the rheumatic diseases 82 (4), 565-573, 2023 | 13 | 2023 |
| A roadmap for investigating preclinical autoimmunity using patient-oriented and epidemiologic study designs: example of rheumatoid arthritis EN Kowalski, G Qian, KMM Vanni, JA Sparks Frontiers in Immunology 13, 890996, 2022 | 12 | 2022 |
| Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective … KR McCarter, T Wolfgang, S Arabelovic, X Wang, K Yoshida, EP Banasiak, ... The Lancet Rheumatology 5 (5), e274-e283, 2023 | 11 | 2023 |
| Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy KMM Vanni, NJ Patel, M DiIorio, E Kowalski, G Qian, CE Cook, SY Ritter, ... RMD open 8 (1), e002082, 2022 | 10 | 2022 |
| Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19 JD Herman, C Atyeo, Y Zur, CE Cook, NJ Patel, KM Vanni, EN Kowalski, ... medRxiv, 2022 | 6 | 2022 |
| Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target … JS Hanberg, X Fu, X Wang, NJ Patel, Y Kawano, A Schiff, EN Kowalski, ... The Lancet Rheumatology 6 (1), e21-e30, 2024 | 5 | 2024 |
| Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines against COVID-19 infection among patients with systemic autoimmune rheumatic diseases on immunomodulatory medications CE Cook, NJ Patel, X Fu, X Wang, Y Kawano, KMM Vanni, G Qian, ... The Journal of rheumatology 50 (5), 697-703, 2023 | 5 | 2023 |
| Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study RK Venkat, X Wang, NJ Patel, Y Kawano, A Schiff, EN Kowalski, CE Cook, ... Rheumatology, kead662, 2023 | 4 | 2023 |
| Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases JD Herman, C Atyeo, Y Zur, CE Cook, NJ Patel, KM Vanni, EN Kowalski, ... Science translational medicine 15 (712), eadf6598, 2023 | 4 | 2023 |
| DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: a prospective study M Di Iorio, CE Cook, KMM Vanni, NJ Patel, KM D’Silva, X Fu, J Wang, ... medRxiv, 2022 | 4 | 2022 |
| Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease PA Juge, K Hayashi, GC McDermott, KMM Vanni, E Kowalski, G Qian, ... Seminars in Arthritis and Rheumatism 64, 152312, 2024 | 3 | 2024 |
| Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: a case-control study EN Kowalski, X Wang, NJ Patel, Y Kawano, CE Cook, KMM Vanni, G Qian, ... Seminars in Arthritis and Rheumatism 63, 152286, 2023 | 3 | 2023 |
| Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study AE Schiff, X Wang, NJ Patel, Y Kawano, EN Kowalski, CE Cook, ... medRxiv, 2023 | 3 | 2023 |
| Breakthrough COVID-19 after tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases Y Kawano, X Wang, NJ Patel, G Qian, E Kowalski, KJ Bade, KMM Vanni, ... The Journal of Rheumatology 51 (3), 305-312, 2024 | 2 | 2024 |
| Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer KR McCarter, S Arabelovic, X Wang, T Wolfgang, K Yoshida, G Qian, ... Seminars in Arthritis and Rheumatism 64, 152335, 2024 | 2 | 2024 |
